TherapeuticsMD Inc (TXMD) Director Brian Bernick Sells 91,400 Shares

TherapeuticsMD Inc (NASDAQ:TXMD) Director Brian Bernick sold 91,400 shares of the stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $4.96, for a total transaction of $453,344.00. Following the sale, the director now directly owns 242,000 shares in the company, valued at approximately $1,200,320. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Brian Bernick also recently made the following trade(s):

  • On Monday, December 3rd, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.07, for a total transaction of $926,796.00.
  • On Tuesday, November 20th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.74, for a total transaction of $866,472.00.
  • On Friday, November 9th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.88, for a total transaction of $892,064.00.
  • On Friday, October 19th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.56, for a total transaction of $1,016,368.00.
  • On Friday, October 5th, Brian Bernick sold 91,400 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.93, for a total transaction of $542,002.00.
  • On Friday, September 28th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $6.59, for a total transaction of $1,204,652.00.
  • On Thursday, September 13th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $6.30, for a total transaction of $1,151,640.00.

Shares of NASDAQ:TXMD opened at $4.63 on Friday. The company has a market capitalization of $1.15 billion, a P/E ratio of -12.51 and a beta of 1.35. TherapeuticsMD Inc has a fifty-two week low of $4.30 and a fifty-two week high of $7.66. The company has a debt-to-equity ratio of 0.55, a quick ratio of 7.15 and a current ratio of 7.23.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Wednesday, November 7th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.06. The firm had revenue of $3.47 million for the quarter, compared to analysts’ expectations of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The firm’s revenue was down 21.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.07) earnings per share. As a group, analysts predict that TherapeuticsMD Inc will post -0.58 earnings per share for the current fiscal year.

Several analysts have recently issued reports on the stock. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Friday, September 21st. Oppenheimer set a $14.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, September 26th. Cantor Fitzgerald set a $27.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Thursday, September 27th. BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, September 7th. Finally, Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, August 25th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $13.45.

A number of large investors have recently modified their holdings of TXMD. Principal Financial Group Inc. raised its holdings in TherapeuticsMD by 84.4% in the first quarter. Principal Financial Group Inc. now owns 59,178 shares of the company’s stock valued at $288,000 after acquiring an additional 27,081 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in TherapeuticsMD in the second quarter valued at approximately $352,000. Raymond James Financial Services Advisors Inc. raised its holdings in TherapeuticsMD by 18.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 213,522 shares of the company’s stock valued at $1,332,000 after acquiring an additional 33,480 shares in the last quarter. TD Asset Management Inc. raised its holdings in TherapeuticsMD by 24.7% in the second quarter. TD Asset Management Inc. now owns 427,602 shares of the company’s stock valued at $2,668,000 after acquiring an additional 84,700 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado raised its holdings in TherapeuticsMD by 2,545.7% in the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after acquiring an additional 1,031,000 shares in the last quarter. 72.66% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/12/07/therapeuticsmd-inc-txmd-director-brian-bernick-sells-91400-shares.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply